Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics N.V (PRQR) EBT: 2013-2024

Historic EBT for ProQR Therapeutics N.V (PRQR) over the last 12 years, with Dec 2024 value amounting to -$29.9 million.

  • ProQR Therapeutics N.V's EBT fell 44.50% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.2 million, marking a year-over-year decrease of 79.87%. This contributed to the annual value of -$29.9 million for FY2024, which is 0.69% up from last year.
  • Per ProQR Therapeutics N.V's latest filing, its EBT stood at -$29.9 million for FY2024, which was up 0.69% from -$30.1 million recorded in FY2023.
  • In the past 5 years, ProQR Therapeutics N.V's EBT registered a high of -$29.9 million during FY2024, and its lowest value of -$71.8 million during FY2021.
  • Its 3-year average for EBT is -$41.8 million, with a median of -$30.1 million in 2023.
  • As far as peak fluctuations go, ProQR Therapeutics N.V's EBT tumbled by 35.29% in 2021, and later surged by 54.00% in 2023.
  • Yearly analysis of 5 years shows ProQR Therapeutics N.V's EBT stood at -$53.1 million in 2020, then crashed by 35.29% to -$71.8 million in 2021, then climbed by 8.92% to -$65.4 million in 2022, then soared by 54.00% to -$30.1 million in 2023, then climbed by 0.69% to -$29.9 million in 2024.